440 related articles for article (PubMed ID: 32950003)
1. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.
Masiá M; Fernández-González M; Padilla S; Ortega P; García JA; Agulló V; García-Abellán J; Telenti G; Guillén L; Gutiérrez F
EBioMedicine; 2020 Oct; 60():102999. PubMed ID: 32950003
[TBL] [Abstract][Full Text] [Related]
2. Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade.
Masiá M; Fernández-González M; García JA; Padilla S; García-Abellán J; Botella Á; Mascarell P; Agulló V; Gutiérrez F
EBioMedicine; 2022 Aug; 82():104153. PubMed ID: 35816896
[TBL] [Abstract][Full Text] [Related]
3. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
To KK; Tsang OT; Leung WS; Tam AR; Wu TC; Lung DC; Yip CC; Cai JP; Chan JM; Chik TS; Lau DP; Choi CY; Chen LL; Chan WM; Chan KH; Ip JD; Ng AC; Poon RW; Luo CT; Cheng VC; Chan JF; Hung IF; Chen Z; Chen H; Yuen KY
Lancet Infect Dis; 2020 May; 20(5):565-574. PubMed ID: 32213337
[TBL] [Abstract][Full Text] [Related]
4. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019.
Kowitdamrong E; Puthanakit T; Jantarabenjakul W; Prompetchara E; Suchartlikitwong P; Putcharoen O; Hirankarn N
PLoS One; 2020; 15(10):e0240502. PubMed ID: 33035234
[TBL] [Abstract][Full Text] [Related]
5. RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients.
Eberhardt KA; Meyer-Schwickerath C; Heger E; Knops E; Lehmann C; Rybniker J; Schommers P; Eichenauer DA; Kurth F; Ramharter M; Kaiser R; Holtick U; Klein F; Jung N; Di Cristanziano V
Viruses; 2020 Sep; 12(9):. PubMed ID: 32962125
[TBL] [Abstract][Full Text] [Related]
6. Lack of tocilizumab effect on mortality in COVID19 patients.
Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M
Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534
[TBL] [Abstract][Full Text] [Related]
7. Preemptive interleukin-6 blockade in patients with COVID-19.
Guillén L; Padilla S; Fernández M; Agulló V; García JA; Telenti G; García-Abellán J; Botella Á; Gutiérrez F; Masiá M
Sci Rep; 2020 Oct; 10(1):16826. PubMed ID: 33033405
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
9. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
[TBL] [Abstract][Full Text] [Related]
10. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
[TBL] [Abstract][Full Text] [Related]
12. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study.
Zhang J; Hao Y; Ou W; Ming F; Liang G; Qian Y; Cai Q; Dong S; Hu S; Wang W; Wei S
J Transl Med; 2020 Oct; 18(1):406. PubMed ID: 33121497
[TBL] [Abstract][Full Text] [Related]
13. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
Zhao M
Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
Wang L; Peng X; Wang ZH; Cai J; Zhou FC
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5783-5787. PubMed ID: 32495916
[TBL] [Abstract][Full Text] [Related]
15. Antibody responses to SARS-CoV-2 in patients with COVID-19.
Long QX; Liu BZ; Deng HJ; Wu GC; Deng K; Chen YK; Liao P; Qiu JF; Lin Y; Cai XF; Wang DQ; Hu Y; Ren JH; Tang N; Xu YY; Yu LH; Mo Z; Gong F; Zhang XL; Tian WG; Hu L; Zhang XX; Xiang JL; Du HX; Liu HW; Lang CH; Luo XH; Wu SB; Cui XP; Zhou Z; Zhu MM; Wang J; Xue CJ; Li XF; Wang L; Li ZJ; Wang K; Niu CC; Yang QJ; Tang XJ; Zhang Y; Liu XM; Li JJ; Zhang DC; Zhang F; Liu P; Yuan J; Li Q; Hu JL; Chen J; Huang AL
Nat Med; 2020 Jun; 26(6):845-848. PubMed ID: 32350462
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M;
J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.
Suhandynata RT; Hoffman MA; Kelner MJ; McLawhon RW; Reed SL; Fitzgerald RL
J Appl Lab Med; 2020 Sep; 5(5):908-920. PubMed ID: 32428207
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 viral load is associated with increased disease severity and mortality.
Fajnzylber J; Regan J; Coxen K; Corry H; Wong C; Rosenthal A; Worrall D; Giguel F; Piechocka-Trocha A; Atyeo C; Fischinger S; Chan A; Flaherty KT; Hall K; Dougan M; Ryan ET; Gillespie E; Chishti R; Li Y; Jilg N; Hanidziar D; Baron RM; Baden L; Tsibris AM; Armstrong KA; Kuritzkes DR; Alter G; Walker BD; Yu X; Li JZ;
Nat Commun; 2020 Oct; 11(1):5493. PubMed ID: 33127906
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of viral load and antibody response in relation to COVID-19 severity.
Wang Y; Zhang L; Sang L; Ye F; Ruan S; Zhong B; Song T; Alshukairi AN; Chen R; Zhang Z; Gan M; Zhu A; Huang Y; Luo L; Mok CKP; Al Gethamy MM; Tan H; Li Z; Huang X; Li F; Sun J; Zhang Y; Wen L; Li Y; Chen Z; Zhuang Z; Zhuo J; Chen C; Kuang L; Wang J; Lv H; Jiang Y; Li M; Lin Y; Deng Y; Tang L; Liang J; Huang J; Perlman S; Zhong N; Zhao J; Malik Peiris JS; Li Y; Zhao J
J Clin Invest; 2020 Oct; 130(10):5235-5244. PubMed ID: 32634129
[TBL] [Abstract][Full Text] [Related]
20. Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis.
Liu R; Liu X; Yuan L; Han H; Shereen MA; Zhen J; Niu Z; Li D; Liu F; Wu K; Luo Z; Zhu C
Int Immunopharmacol; 2020 Sep; 86():106746. PubMed ID: 32619956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
